CNTG News and Press, Centogene N.V. From 12/18/20

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actiona...

Centogene N.V. (CNTG) Q3 2020 Earnings Conference Call December 16, 2020 08:30 ET Company Participants Sun Kim - Investor Relations Richard Stoffelen - Chief Financial Officer Andrin Oswald - Chief Executive Officer Conference Call Participants Puneet Souda - SVB Leerink Sung Ji Nam - BTIG Ca...

The following slide deck was published by Centogene N.V. in conjunction with their 2020 Q3 earnings call. For further details see: Centogene N.V. 2020 Q3 - Results - Earnings Call Presentation

Centogene (CNTG) reports Q3 results:Revenues increased 212% Y/Y to €36.3M, driven by the continued expansion of our COVID-19 testing offering.Pharma revenues decreased 21%, while Clinical Diagnostics revenues (excl. COVID) decreased 25% compared to Q3 2019.Commercial COVID-19...

Centogene (CNTG): Q3 comprehensive loss of €5.7M.Revenue of €36.3M (+211.9% Y/Y)Shares +7% PM.Press Release For further details see: Centogene reports Q3 results

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actiona...

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutic...

Centogene N.V. (NASDAQ: CNTG) teams up with Alnylam Pharmaceuticals (NASDAQ:ALNY) to launch a new joint clinically screening program targeting the at-risk population for hereditary TransthyRetin-related Amyloidosis (ATTRv).In addition to the genetic screening of the patients, the study w...

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN and MUNICH, Germany, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicia...

Centogene N.V. (CNTG) has expanded its partnership with PTC Therapeutics (PTCT). The companies will work together to provide genetic testing and 3-O-Methyldopa (3-OMD) biomarker analytics to help identify patients with Aromatic L-amino Acid Decarboxylase ((AADC)) deficiency, a rare genet...